ACE and atrial fibrillation: Mohammad et al. 84performed a recent retrospective analysis of 11 studies (11 458 patients on sacubitril/valsartan, 10 128 patients on ACE inhibitors/ARBs) that showed that although sacubitril/valsartan improved mortality versus ACE inhibitors/ARBs, it did not reduce the risk of developing AF.